论文部分内容阅读
食管静脉曲张破裂出血(esophageal varices bleeding,EVB)是肝硬化患者的主要并发症和致死原因,初次发生EVB的死亡率为10%,再次发生出血的死亡率为40%。如何预防消化道再出血是临床治疗肝硬化并发症中较为重要的部分。内镜下食管静脉曲张硬化术(esophageal variciform sclero therapy,EVS)是目前治疗EVB的一种安全、有效方法[1]。国内外文献对内镜硬化术治疗EVB的近期疗效进行了大量报道。本研究拟回顾性分析安徽省阜阳市第二人民医院经内镜下治疗的55例肝硬化患者,旨在研究内镜硬化术在消化道出血的二级预防中的
Esophageal varices bleeding (EVB) is a major complication and cause of death in patients with cirrhosis. The initial EVB death rate was 10% and the rate of recurrent bleeding was 40%. How to prevent gastrointestinal rebleeding is a more important part of the clinical treatment of complications of liver cirrhosis. Endoscopic esophageal variciform sclerotherapy (esophageal variciform sclero therapy, EVS) is currently a safe and effective treatment of EVB [1]. Domestic and foreign literature on the recent efficacy of endoscopic sclerotherapy for the treatment of EVB carried out a large number of reports. This study was intended to retrospectively analyze 55 endoscopic liver cirrhosis patients treated by endoscopy in the Second People’s Hospital of Fuyang City, Anhui Province. The aim of this study was to investigate the value of endoscopic sclerotherapy in secondary prevention of gastrointestinal bleeding